Comparison of clinical characteristics of non-B non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma and prognosis in Uighur patients / 中华肿瘤杂志

<p><b>OBJECTIVE</b>This study was aimed to understand the clinical characteristics and prognosis in Uighur patients with Non-B Non-C hepatocellular carcinoma (HCC) and virus-related HCC.</p><p><b>METHODS</b>We retrospectively analyzed the clinical data of 301 Uighur HCC patients, among them, there were 145 NBC-HCC cases and 156 virus-related HCC cases. The overall survival rates of the patients were analyzed by Kaplan-Meier method, and the factors that may influence the prognosis and survival of NBC-HCC patients were analyzed using univariate (Log rank test) and multivariate Cox proportional hazard model.</p><p><b>RESULTS</b>The differences of the gender, living region, history of diabetes, body mass index (BMI), history of cirrhosis, TNM stage, Child-Pugh scores, total bilirubin, and AFP level between the NBC-HCC group and viral-HCC group were statistically significant (P < 0.05 for all). The 1-, 2-, 3- and 5-year survival rates were 35.6%, 20.3%, 12.6%, and 4.5%, respectively, for all the 301 patients, and no significant difference between these two groups in terms of OS (P > 0.05). Multivariate analysis by Cox model showed that age, TNM staging, PVTT, Child-Pugh scores, TACE combined with radiotherapy or RFA were significant independent prognostic factors (all P < 0.05).</p><p><b>CONCLUSIONS</b>The clinical characteristics in Uighur patients with non-B non-C HCC and hepatitis virus-related HCC are not all the same and HCC in Xinjiang region has certain regional characteristics and features. Age, TNM stages, portal vein tumor thrombus, Child-Pugh scores, and TACE combined with radiotherapy or RFA are significant independent prognostic factors.</p>

Diagnostic value of Golgi-73 and AFP alone or combination in primary hepatocelluar carcinoma / 中华检验医学杂志

Objective To explore the application value of Golgi protein-73 (GP73)and AFP in single and combining form in the diagnosis of primary hepatocelluar carcinoma (PHC).Methods Eighty PHC,65 liver cirrhosis,54 chronic hepatitis patients and 50 controls were selected in the First Afiliated Hospital in Xinjiang Medical University from May to September in 2011,GP73 was detected by ELISA and AFP was measured by clinical chemiluminescence.The sensitivity and specificity of each parameter in single and combining form were evaluated.Results Serum GP73 in PHC group 282.0(163.6-366.7) μg/L,liver cirrhosis group 211.8(107.5-295.7) μg/L,chronic hepatitis group 100.3(61.8-191.3) μg/L and control group 58.3(43.4-83.6) μg/L was tested by Kruskal-Wallis(H =106.6,P ＜0.01).GP73 in PHC group was further compared with liver cirrhosis group,chronic hepatitis group and control group using MannWhitney test,significance was found,(U was 1796.0,826.5,154.0,respectively,all P ＜0.01).In the single form,the sensitivity of GP73 [82.5％ (66/80)] was higher than AFP [66.3％ (53/80),x2 =4.65,P ＜0.05],but the specificity of GP73 [63.3％ (107/169)] was lower than AFP [88.7％ (150/169),x2 =28.91,P ＜0.05].There were 27 AFP negative cases in PHC group,but 22 of them were GP73 positive,making the positive rate of GP73 [81.5％ (22/27)] in PHC patients with AFP negative.There were 14 GP73 negative cases of in PHC group,but 9 of them were AFP positive,making the positive rate of AFP [64.3％ (9/14)] in PHC patients with GP73 negative.In series diagnostic test,the specificity of combining form [95.9％ (162/169)] was higher than AFP [88.7 ％ (150/169),x2 =6.00,P ＜ 0.05] ; in parallel diagnostic test,the sensitivity of combining form [93.8％ (75/80)] was higher than GP73 [82.5％(66/80),x2 =4.84,P ＜0.05].In PHC group,52 patients with HBV infection,10 patients with HCV infection and 18 patients without virus infection,GP73 was 309.5 (170.5-370.5) μg/L,351.0 (274.7-397.9) μg/L and 210.1 (156.8-306.7) μg/L,respectively,no significance was found (H =4.0,P ＞0.05).Conclusion GP73 and AFP have a complementary feature of sensitivity and specificity in the early diagnosis of PHC,some PHC cases with AFP negative can be avoided missing efficiently by parallel diagnostic test.

Dosimetric comparison of postoperative intensity-modulated radiotherapy for stage Ⅱ - Ⅲ rectal cancer / 中华放射肿瘤学杂志

ObjectiveTo explore the optimal method of protecting bone marrow in postoperative concurrent chemoradiotherapy of stage Ⅱ - Ⅲ rectal cancer by comparing two techniques of intensitymodulated radiotherapy (IMRT). MethodsFifteen patients with stage Ⅱ - Ⅲ rectal cancer after surgery had CT simulation. Clinical target volume, small bowel, bladder and bone marrow were contoured. Two IMRT treatment plannings with and without bone marrow-sparing (BMS-IMRT and IMRT) were separately designed. The dose distribution was compared based on that 95％ of the planning target volume received the prescribed dose. ResultsBMS-IMRT had an advantage over IMRT in terms of conformity indices ( 1. 06∶1. 04, t =- 2. 61, P =0. 023 ), but inferior to I M RT for homogeneity indices ( 0. 81 : 0. 75, t =- 2. 34, P =0.037)).Compared with IMRT, BMS-IMRT reduced the V5, V10, V20, V30, V40 of bone marrow (97.09％∶98.72％, t=-2.34, P=0.037;92.38％∶96.46％, t=-2.41, P=0.033;83.36％∶91.70％, t=-3. 18, P=0.008;51.47％∶69.65％, t=-4.92, P=0.000;36.34％∶49.57％, t=-2.66, P =0. 021 ). The doses received by small bowel and bladder were similar between BMS-IMRT and IMRT, except that the V20 of bladder was lower in BMS-IMRT (77. 32％∶92. 39％, t =-3.52, P=0. 004). Conclusions BMS-IMRT reduces low dose volume of bone marrow without increasing dose to other risk organs.BMS-IMRT might reduce acute hematologic toxicity and increase the feasibility of postoperative concurrent chemoradiotherapy in stage Ⅱ -Ⅲ rectal cancer.

Analysis on proteomic fingerprints of the advanced gastric cancer patients when LGT fingerprints changing / 肿瘤研究与临床

Objective To analyze the disposition characteristic of LGT fingerprints and the related fingerprints for advanced gastric carcinoma patients when the LGT fingerprints changing. Methods SELDI and CM10 protein chip was used to detect the serum protein fingerprints of 81 cased of advanced gastric cancer patients. After 1 year follow-up, all the patients were detected by SELDI again. According to the expression condition of LGT fingerprints, the patients were divided into 4 groups: A group(LGT changing from negative to positive) 25 cases, B group (LGT changing from positive to negative) 15 cases, C group (LGT fingerprints keeping negative) 29 cases and D group (LGT fingerprints keeping positive) 12 cases. The influencing factor should be rejected. And the remaining fingerprints were LGT fingerprints' subtypes and therelated fingerprints. The different proteomic fingerprints were analyzed by Biomarker Wizard 3.1 Software.Results After rejecting the influencing fingerprints, the up-regulation fingerprints in A group were 11473, 11821, 11664, 11409, 11552 and 11947 (M/Z), and no down-regulation fingerprints. In B group, 3264 was upregulation, and 6523, 11509, 11669, 11413, 11351 and 6483 were down-regulation. In C and D group, there was not statistically differential protein fingerprint. Conclusion M/Z up-regulating fingerprints including 11473, 11821, 11664, 11409, 11552 and 11947 can be regarded as the subtype of LGT when it changing from negative to positive; down-regulating including 11509, 11669, 11413 and 11351 can be regarded as the subtype of LGT when it changing from positive to negative; 3264 up-regulating and 6523 and 6483 downregulating can be regarded as the related fingerprints when LGT changing from positive to negative; and when LGT keeping negative or positive in patients with advanced gastric cancer, there was no differential protein fingerprints.